KẾT QUẢ ĐIỀU TRỊ PHÁC ĐỒ DOCETAXEL-CISPLATIN TRONG UNG THƯ BIỂU MÔ THỰC QUẢN GIAI ĐOẠN TÁI PHÁT, DI CĂN

Abstract

Objective: This study aimed to evaluate the efficacy and safety of the Docetaxel–Cisplatin regimen in patients with recurrent or metastatic esophageal carcinoma. Methods: A descriptive study combining retrospective and prospective data collection with longitudinal follow-up was conducted at K Hospital from June 2018 to June 2023. A total of 55 patients who met the diagnostic criteria, received chemotherapy with the Docetaxel–Cisplatin regimen, and had complete clinical data were included. Treatment response was assessed according to RECIST 1.1 criteria, and progression-free survival (PFS) was analyzed. Adverse events were recorded using CTCAE version 5.0. Results: The overall response rate (ORR) was 50.9%, including 3.6% complete response and 47.3% partial response. Clinical benefit rate was 80%. The median PFS was 5.2 months. Factors such as age, histological grade, site, and number of metastases did not show statistically significant impacts on PFS. Patients who received ≥90% of the chemotherapy dose had a higher median PFS (6.1 months vs. 5.1 months; p = 0.006). The most common adverse events were neutropenia (30.9% grade 3–4), nausea (64.3%), and alopecia (71.4%), mostly mild and manageable. Conclusion: The Docetaxel–Cisplatin regimen is a feasible treatment option, showing good clinical efficacy and acceptable toxicity for patients with metastatic esophageal carcinoma in Vietnam.